MindCure Health (CSE:MCUR) CEO Kelsey Ramsden tells Proactive the Vancouver, Canada-based psychedelics-focused group has closed $23M, with half of the funds going towards fundamental research using psilocybin, ketamine, and ibogaine to treat pain from head trauma.
Ramsden says the remaining funds will be used towards the build-out of its digital therapeutics platform, which houses the 'largest data repository of known psychedelics experience.'